As we enter the 21st century, advances in the treatment of cancer will be significant and the patient will benefit in terms of quality of life. It is not unreasonable to anticipate a time when many cancer patients are managed as if they were chronically ill.

These thoughts are being shaped and driven by a variety of forces:

• A new paradigm that would make use of the patient's natural immune and control systems
• The vast array of developing knowledge in the area of cells
• New products under development based on the immune system and cell function or death
• Critical strategic alliances between researched-based pharmaceutical and biotech

This MarketResearch.com study focuses on the five key segments that will impact advanced cancer therapy:

• Immunological and vaccine approaches
• Antiproliferative approaches
• Photodynamic therapy
• Gene therapy approaches
• Cell cycle and apoptosis approaches

The report provides detailed company profiles, which include:

• Current products
• Product pipeline
• Key strategic alliances (large and small)
• Discussions of the core technologies R&D activities

The study provides forecast information and examines selected dynamics and cancer statistics for the 7 major world markets.

Additional Information

Methodology
For this report, the areas of advanced cancer therapy have been divided into five key segments. These include:

• Immunological and Vaccine Approaches
• Antiproliferative Approaches (Angiogenesis, Metastasis)
• Photodynamic Therapy
• Gene Therapy Approaches
• Cell-cycle and Apoptosis Approaches

Some mention is made of hematopoietic restoration and support, i.e., bone marrow transplantation, peripheral blood stem cell transplantation, in text and tables. This field does contribute to the overall cancer picture but is not significantly commercial. The exceptions to this are restorative drugs for neutropenia, which are considered elsewhere in the report and in perspective to advanced cancer therapeutics as a whole.

This report focuses primarily on the technology of advanced cancer therapeutics, the options that they present, and the progress being made in these fields. The major market effects, with the potential of a breakthrough drug always a possibility, are expected to be long term and gradually established. Therefore, the technology trends in conjunction with the growing paradigm shift in cancer therapy present the most informative picture of advances in cancer therapeutics.

This report covers current therapeutics, such as cytotoxic chemotherapeutics, only in the broadest sense. It does not go into detail about the dynamics of these various drugs in the marketplace. It does, however, discuss the impacts that advanced cancer therapeutic technologies will have on existing therapeutics markets on the whole. Market analysis for this report considers the cancer therapeutics markets in the seven major world healthcare markets: the United States, France, Germany, Italy, Japan, Spain and the United Kingdom. This report does not consider instrumentation, such as radiotherapy systems, surgical devices, etc., but focuses on pharmaceutical-based products and technologies. The focus on pharmaceutical-based technologies is further narrowed to those advanced cancer therapeutics with the potential to become first-line therapies.

The analysis presented in this report is based on data from a combination of government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including oncologists, pathologists, research scientists, business development managers, and marketing managers.

Size and Growth of the Market

As shown in Table 1-1 and Figure 1-1, the current market for cancer therapeutics is generally divided into two major segments, primary (first line) therapies and supportive therapies. Primary therapies include cytotoxic drugs and hormonal drugs. Supportive, or adjunct, therapies include blood restoration products (hematopoietic), pain relief products, and antibiotics/antifungals to treat opportunistic infections. Figure 1-2 provides a view of the current distribution of these markets by percentage.

The current market for cancer therapeutics in the seven world healthcare markets amounts to approximately US$ 11.4 billion. This is expected to grow at an annual compound rate of approximately 6.3% through 2006, at which time the market will have grown to about US$ 16.6. This growth is being fueled by:

• The increase in population, notable in the United States and Japan. Despite a decade of decreasing cancer incidence rates, the number of cancer patients is still increasing due to increases in population.
• The aging of the population. As cancer incidence increases with age, an aging population will proportionately increase the cancer incidence.
• Increasing survival rates. The longer a cancer patient lives and requires treatment, the longer they require drugs. With a shift in treatment paradigm, cancer patients will use such drugs for much longer, increasing market size.

Press Release

New York, January 31/PRNewswire - MarketResearch.com, the business information center, announced the release of a new research study “Advances in Cancer Therapy” from Kalorama Information. According to this study, oncologists are moving away from the long-held belief that the primary goal of cancer treatment is to destroy the tumor at all costs. Instead, doctors are now looking for marginal gains in survival rates without exposing cancer patients to severe treatments. Fueled by a more thorough understanding of the mechanisms of cancer, better-educated patients and advances in genetics and genomics, the desire to provide patients with a higher quality of life during treatment is becoming more attainable.

The five promising technologies examined in this study offer less invasive treatment options to prohibit the spread of cancer. New immunological approaches control cancer reemergence with a vaccine prepared from the tumor cells of the patient, encouraging the body to mount a specific autoimmune attack. With new research in angiogenesis, the antiproliferative approach can prevent the creation of new vasculature in tumor tissue, effectively “starving “ the tumor. Providing an alternative to radiation and surgery for early stage cancer treatment, photodynamic therapy relies on the passage of light through tissue to destroy a tumor. Although this non-invasive procedure is an attractive option, tumors can reside at depths unreachable by light, rendering photodynamic therapy ineffective. Cell cycle/apoptosis (programmed cell death) relies on the ability of cells to self-destruct when damaged or aged and has been successfully used in treating certain types of leukemia. New gene therapies introduces a therapeutic agent to a gene or gene-product to change the cellular phenotype from neoplastic to normal.

The current market for cancer therapeutics is nearly $12 billion and expected to reach over $16 billion by 2006, says this report. The growth is due to the increase in population (notably the United States and Japan), the overall aging of the population and increasing survival rates of cancer patients.

Issues Addressed:

• Current and Projected Market Growth
• Factors Affecting Market Growth
• Disease Management Techniques
• New Product Development
• Research & Development Trends
• Genetics & Genomics
• Commercial Outlook by Category
• Competitive Overview

Companies Discussed:

• Abgenix
• Agouron Pharmaceuticals
• Amgen
• Biomira
• Bristol-Myers Squibb
• British Biotech
• CollaGenex Pharmaceutical
• Corixa
• DUSA Pharmaceuticals
• Genta
• Genzyme Molecular Oncology
• Isis Pharmaceuticals
• Morphosys
• Onyx Pharmaceuticals
• Pharmacyclics
• Ribozyme Pharmaceuticals
• Sugen
• Vical

Categories Covered:

• Immunological And Vaccine Approaches
• Antiproliferative Approaches
• Photodynamic Therapy
• Gene Therapy
• Cell Cycle and Apoptosis

Tables and Graphs:

• Market Size, 1998-2006
• Estimated Cancer Prevalence, 1998-2006
• Therapeutic Treatment Options
• Emerging Cancer Therapies
• Clinical Trials Involving Cancer Immunotherapy
• Key Angiogenesis Inhibitors in Development
• Clinical Trials Involving Photodynamic Therapy
• Cell Cycle Regulators by Phase
• Physical & Chemical Gene Transfer Technologies
• Viral Vector Gene Transfer Technologies

Hours of Research: 750

Related Reports:

The Worldwide Market for Cancer Diagnostics, 4th Edition
Apr 1, 2010 - KLI2504623 - $4,200.00

Kalorama Information Library and Annual Subscription
Jan 1, 2010 - KLI1600708 - $55,000.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00

Cell Culture: The World Market for Media, Sera and Reagents, 2nd Edition
May 1, 2009 - KLI2091313 - $3,995.00

Women's Health: Worldwide Prescription Drug Markets
Feb 1, 2009 - KLI2071673 - $2,995.00

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
Nov 1, 2008 - KLI1646591 - $3,995.00

The Worldwide Market for Cancer Diagnostics, 3rd Edition
Mar 1, 2008 - KLI1393082 - $3,995.00

Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market
May 1, 2007 - KLI1469934 - $995.00

Cancer Therapeutics: The Worldwide Market , 2nd Edition
Feb 1, 2007 - KLI1365882 - $2,500.00

Biomarkers: A Market Briefing
Jan 1, 2007 - KLI1059917 - $1,200.00